C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
Viola Klück,Rosanne C. van Deuren,Giulio Cavalli,Amara Shaukat,Peer Arts,Maartje C. P. Cleophas,Tania O Crișan,Anne-Kathrin Tausche,Philip Riches,Nicola Dalbeth,Lisa K. Stamp,Jennie Harré Hindmarsh,T.L.Th.A. Jansen,Matthijs Janssen,Marloes Steehouwer,Stefan H. Lelieveld,Maartje van de Vorst,Christian Gilissen,Lorenzo Dagna,Frank L. van de Veerdonk,Elan Z. Eisenmesser,Soohyun Kim,Tony R. Merriman,Alexander Hoischen,Mihai G. Netea,Charles A. Dinarello,Leo A. B. Joosten +26 more
TL;DR: The carrier status of p.(N182S)(rs752113534) was associated with increased risk of developing gout in hyperuricaemic individuals of Polynesian ancestry and the therapeutic potential of recombinant IL-37 for the treatment of gouty arthritis was highlighted.
Journal ArticleDOI
ATP-Induced IL-1β Specific Secretion: True Under Stringent Conditions.
TL;DR: This work challenges the concept that secretion of IL-1β is due to cytotoxic effects of ATP with P2X7 receptor-activation-related cell death, since there is no increase in cell death andIL-1α and IL-18 are not released in the same cultures.
Patent
Truncated protein of interleukin-1
Philip E. Auron,Andrew C. Webb,Lee Gehrke,Charles A. Dinarello,Lanny J. Rosenwasser,Alexander Rich,Sheldon M. Wolff +6 more
TL;DR: In this paper, the truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail, and they are useful to induce the production of IL-2 by activated T-cells.
Journal ArticleDOI
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Jonathan B. Angel,Bradford M. Saget,Sean P. Walsh,Tim F. Greten,Charles A. Dinarello,Paul R. Skolnik,Stefan Endres +6 more
TL;DR: Rolipram is a potent inhibitor HIV-1 replication and therefore deserves further investigation as a potential therapeutic agent in the treatment of HIV -infected patients.
Journal ArticleDOI
Inhibition of early airway neutrophilia does not affect development of airway hyperresponsiveness
Christian Taube,Jerry A. Nick,Britta Siegmund,Catherine Duez,Katsuyuki Takeda,Yeong Ho Rha,Jung Won Park,Anthony Joetham,Katie R. Poch,Azzeddine Dakhama,Charles A. Dinarello,Erwin W. Gelfand +11 more
TL;DR: It is demonstrated that early neutrophil influx following allergen challenge is mediated by IL-1, IL-18, and p38MAPK, and the effects of inhibiting p38 MAPK in decreasing AHR indicate activities independent of its prevention of neutrophils accumulation.